Sigyn Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Sigyn Therapeutics generated cash of -$1,383,210, which is more than the previous year. Cash used in financing activities reached the amount of $1,386,544 last year. Net change in cash is therefore $3,334.
Cash Flow
| 2014 | -44.44K | -3.46K | 48K |
|---|---|---|---|
| 2015 | -83.82K | -12.45K | 735K |
| 2016 | -131.05K | -118.11K | 208.70K |
| 2017 | -400.00K | -79.06K | 339.05K |
| 2018 | -286.11K | -8.45K | 292.46K |
| 2019 | -143.68K | 100K | 36.68K |
| 2020 | -829.80K | -10.79K | 925.01K |
| 2021 | -1.77M | -29.26K | 2.06M |
| 2022 | -1.83M | -860 | 1.49M |
| 2023 | -1.38M | 0 | 1.38M |
SIGY Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 8.35K | 340.95K | 84.40K | 0 | 7.49K | 9.59K | 149.60K | 341.71K | 95 | 0 |
Operating activities | ||||||||||
Net income | -4.14M | -2.92M | -3.00M | -1.25M | -3.33M | -2.62M | -4.25M | -831.53K | -2.69M | -387.54K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 8.85K | 10.45K | 19.15K | 11.3K | 75.32K | 247.38K | 235.79K | 86.45K | 1.15K | 0 |
Stock-based compensation expense | 215.55K | 0 | 249.1K | 0 | 3.84K | 10.13K | 62.31K | 0 | 1.39M | 0 |
| Deferred income tax benefit | 215.55K | 0 | 249.1K | 0 | 3.84K | 10.13K | 62.31K | 0 | 1.39M | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | -34.29K | 7.63K | -9.73K | 5.33K | -29.20K | -1.02K |
Inventories | 0 | 0 | 0 | 0 | 135.48K | 2.54K | -2.53K | 1.17K | 9.93K | 25.24K |
Accounts payable | 196.62K | 287.84K | 23.66K | 15.09K | -12.22K | -138.80K | 177.06K | 334.20K | 191.41K | 0 |
Cash generated by operating activities | -1.38M | -1.83M | -1.77M | -829.80K | -143.68K | -286.11K | -400.00K | -131.05K | -83.82K | -44.44K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -860 | -29.26K | -10.79K | 0 | -8.45K | -79.06K | -118.11K | -12.45K | -3.46K |
Acquisitions Net | 0 | 0 | 0 | 0 | 100K | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | -860 | -29.26K | -10.79K | 100K | -8.45K | -79.06K | -118.11K | -12.45K | -3.46K |
Financing activities | ||||||||||
Common Stock Issued | 1.52M | 145.10K | 1.86M | 396K | 0 | 205.76K | 0 | 200K | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 1.31M | 1.56M | -55K | -925.01K | 0 | -112.55K | 339.05K | -208.70K | 240.12K | 0 |
Cash used in financing activities | 1.38M | 1.49M | 2.06M | 925.01K | 36.68K | 292.46K | 339.05K | 208.70K | 735K | 48K |
Net Change In Cash | 3.33K | -332.6K | 256.55K | 84.40K | -6.99K | -2.09K | -140.01K | -192.10K | 638.72K | 95 |
Cash at end of period | 11.69K | 8.35K | 340.95K | 84.40K | 500 | 7.49K | 9.59K | 149.60K | 638.82K | 95 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |